As Medicare Advantage grows, first-time enrollees demonstrate increasing demographic and clinical diversity, indicating that benefits should be designed to reflect the population’s changing ...

Risk-bearing provider organizations rely on physicians to achieve cost savings. The literature on physician-mediated interventions to reduce costs is scant and provides little guidance on effective ...

A two-step approach pooled indication-specific response rates, then generated naïve odds ratios via random-effects models, reflecting limited head-to-head evidence across BTK inhibitors. Across ...

Digital access and care continuity correlated strongly with telemedicine uptake, including patient portal use (OR 1.44) and returning-visit status, while new-patient encounters were markedly less ...

Using nationally representative data, the authors found that for common physician-administered drugs, hospitals’ unilaterally set cash prices are frequently lower than their median—and sometimes even ...

Medicaid/CHIP surveillance demonstrated an 11.4% relative rise in pediatric diabetes prevalence, including a 24.3% increase in type 2 diabetes, with disparities by geography, sex, and region.

The recent FDA approval of teclistamab (Tecvayli) in combination with daratumumab and hyaluronidase-fihj (Darzalex Faspro), both from Janssen Biotech, Inc, marks a significant shift in treating ...

A home blood pressure telemonitoring program effectively reduced blood pressure in real-world clinical settings, but program enrollment expenses increased overall costs.

Clinicians must consider patient comorbidities and therapy safety when selecting immunotherapy for cSCC, says Todd ...

At the Winter Clinical Dermatology Meeting, April W. Armstrong, MD, MPH, professor and chief of dermatology at the UCLA ...

Total RHTP allocations varied widely ($147M–$281M) and did not track state rural population size, yielding extreme per–rural-resident differences across baseline and variable components. Higher ...

Regulatory expansion positions deucravacitinib 6 mg once daily as a first-in-class oral TYK2 option for active PsA, complementing its prior plaque psoriasis indication. POETYK PsA-1 showed significant ...